VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers

Molecular agents targeting the epidermal growth factor receptor (EGFR)‐, anaplastic lymphoma kinase (ALK)‐ or c‐ros oncogene 1 (ROS1) alterations have revolutionized the treatment of oncogene‐driven non‐small‐cell lung cancer (NSCLC). However, the emergence of acquired resistance remains a significa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Sci
Hauptverfasser: Watanabe, Hiromi, Ichihara, Eiki, Kayatani, Hiroe, Makimoto, Go, Ninomiya, Kiichiro, Nishii, Kazuya, Higo, Hisao, Ando, Chihiro, Okawa, Sachi, Nakasuka, Takamasa, Kano, Hirohisa, Hara, Naofumi, Hirabae, Atsuko, Kato, Yuka, Ninomiya, Takashi, Kubo, Toshio, Rai, Kammei, Ohashi, Kadoaki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2021
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8088971/
https://ncbi.nlm.nih.gov/pubmed/33410241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14801
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge